
    
      This is a prospective, randomized, two arm, placebo-controlled, double blind, study that will
      enroll approximately 216 patients at no more than thirty-five (35) international clinical
      sites. Additional blinding measures will be taken in the assessment of study outcomes. The
      dose of the test material (ADRCs)is described in the protocol. The study will include two
      arms.
    
  